Cytomos reports that it is showcasing its flagship cell analytic intelligence platform AuraCyt®, together with its novel Celledonia® benchtop technology, which is designed to boost predictive cell analytics. Current challenges in the bioprocessing space include slow, label-dependent analytical methods that are inefficient to scale-up and provide limited predictive insight, according to Cytomos. The AuraCyt platform measures intrinsic cell physics to generate AI-ready digital fingerprints that reveal the multi-dimensional state and behavior of the cell. The benchtop cell analytics intelligence system combines the compact Celledonia analyzer with the sensors of the AuraCyt modules to transform complex cellular data into actionable insights, notes a Cytomos spokesperson, who points out that this label-free, single-cell analysis system predicts future productivity, stability, and manufacturability. This enables earlier insights and real-time decision-making, lowering risk, providing scalable impact, optimizing process and improving product consistency, says the spokesperson. The operation reportedly provides demonstrable value across various applications, such as reducing CLD timelines by up to 40%, saving up to 65% of resources in lentivirus batch production, and reducing CAR T process time by up to 30%, comments Cytomos’ executive chair, Alan Raymond. The company is showcasing this technology at its pod in BIO Business Forum Zone D (Exhibit Hall 2221 UK Pavillion), from 22-25th of June, 2026. The post Cytomos’ AuraCyt Digital Predictive Cell Analytics Platform Showcased at BIO Conference appeared first on GEN – Genetic Engineering and Biotechnology News.
